中国普通外科杂志2025，Vol.34Issue(7)：1347-1352,6.DOI:10.7659/j.issn.1005-6947.250404
肝细胞癌的新辅助治疗:现状与展望
The neoadjuvant therapy of hepatocellular carcinoma:current status and prospects
摘要
Abstract
Hepatocellular carcinoma(HCC)remains highly prevalent in China and worldwide,with less than 20%of newly diagnosed patients eligible for radical resection and a postoperative 5-year recurrence rate as high as 70%.Perioperative therapy is a key strategy to reduce recurrence,yet evidence for neoadjuvant therapy in HCC is still limited.In recent years,immune checkpoint inhibitors(ICIs)have shown significant progress in HCC treatment,and their potential in the neoadjuvant setting has attracted growing attention.Neoadjuvant immunotherapy can utilize the primary tumor as an antigen reservoir to induce sustained antitumor immunity,and its combination with targeted agents or local therapies may yield synergistic effects.Early studies have demonstrated acceptable safety and preliminary efficacy;however,optimal patient selection,ideal combination strategies,and reliable predictive biomarkers remain to be established.High-quality randomized controlled trials are warranted to verify its impact on long-term survival and to optimize treatment approaches.关键词
癌,肝细胞/肿瘤辅助疗法/免疫检查点抑制剂Key words
Carcinoma,Hepatocellular/Neoadjuvant Therapy/Immune Checkpoint Inhibitors分类
医药卫生引用本文复制引用
赵磊..肝细胞癌的新辅助治疗:现状与展望[J].中国普通外科杂志,2025,34(7):1347-1352,6.基金项目
山东省重点与研发计划重特大疾病"防诊控治康"科技示范工程基金资助项目(2021SFGC0501). （2021SFGC0501）
